A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

Abstract Objectives HER2 is an infrequently mutated driver gene in non‐small cell lung cancer (NSCLC). At present, there has been no comprehensive large‐scale clinical study to establish the optimal first‐line treatment strategy for advanced lung adenocarcinoma (LUAD) with HER2‐Mutant. Besides that,...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Li Wang, Yueran Wu, Zhixuan Ren, Xiangling Chu, Jianing Chen, Li Liu, Jing Zhao, Xin Yu, Mengqing Xie, Chunxia Su
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2024-06-01
Serie:	Cancer Medicine
Soggetti:	efficacy first‐line treatment HER2‐mutant lung adenocarcinoma pyrotinib
Accesso online:	https://doi.org/10.1002/cam4.7335
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!